Chronic pancreatitis: faces, facets, and facts

Peter Layer, Jutta Keller
Medizinische Klinik, Israelitisches Krankenhaus, Lehrkrankenhaus der Universität Hamburg, Deutschland

Only few diseases present with such a wide spectrum of clinical symptoms and therapeutic problems as chronic pancreatitis. This is due, first, to the particular combination of exocrine and endocrine functions provided by this gland, with production of both, digestive (ie aggressive) enzymes and several regulatory peptides crucial for metabolic control. Second, the not easily accessible anatomical location in the centre of various important viscous, parenchymal, vascular and neural structures is critical. Third, there is the typically progressive course of the disease, which may be characterised initially by painful inflammation but preserved function, or by steatorrhea and/or diabetes, with or without pain at any time during its course [1]. And fourth, the clinical picture and course is often dominated by local complications such as pseudocysts, infections, haemorrhage, or obstruction of adjacent structures.

This clinical and pathophysiological heterogeneity explains, why the differential diagnostic work-up as well as therapeutic strategy may be demanding in chronic pancreatitis. It illustrates also why, in contrast to other chronic diseases (such as inflammatory bowel diseases or chronic hepatitis) it has been difficult to design powerful prospective studies. Indeed, the striking scarcity of randomised controlled clinical trials in chronic pancreatitis, a disease with steadily increasing prevalence [2], explains, why much of the scientific evidence on which current management concepts are based is anecdotal.

In a timely and knowledgeable review published in the current issue of this journal [3], Ammann, who has contributed crucially to our present understanding of the clinical manifestation and natural history of chronic pancreatitis [4], has summarised important (including controversial) aspects of our current understanding of alcoholic pancreatitis, and touched several areas of discussion and unsolved problems beyond the role of alcohol.

Important breakthroughs include the discovery of mutations of trypsinogen, SPINK, or CFTR genes that cause, promote and/or modulate entities such as hereditary, idiopathic, and tropical pancreatitis. Moreover, they may help us to explain why only some, but not all individuals consuming alcohol develop pancreatitis. Current hypotheses involve intriguing interrelationships to genetic diseases such as cystic fibrosis. The role of exogenous insults in addition to, or instead of alcohol, such as smoking as independent and likely potentiating causative factors is increasingly recognised. Moreover, the pancreas as an important target of autoimmunity has only recently been acknowledged [5]. On the other hand, while our understanding of the pathogenetic cascades leading to chronic pancreatitis has improved, it nevertheless is still limited, as a few examples might demonstrate.

Thus, it has been shown that mutations of the cationic trypsinogen gene may lead to autosomal dominant hereditary pancreatitis [6]. Other genetic alterations such as loss-of-function mutations of the pancreatic secretory trypsin inhibitor (SPINK1) [7] or a variety of CFTR gene mutations increase susceptibility to chronic pancreatitis [8, 9] but additional factors are needed for manifestation. Therefore, in the vast majority of patients, genetic mechanisms may be of importance but do not explain development of chronic pancreatitis and their exact role still needs to be defined.

Moreover, there is evidence that immunological alterations or diseases may cause or be associated with development of chronic pancreatitis. Most obviously, this has been demonstrated for autoimmune chronic pancreatitis, a disease entity that has been observed mainly in Japan, but is increasingly recognised in Western countries as well. Autoimmune pancreatitis shows specific clinical and morphological characteristics and is associated with other autoimmune phenomena, eg Sjögren’s syndrome, autoimmune thyroiditis and ulcerative colitis [10]. It is particularly important to diagnose this disease early because steroid treatment does not only improve the patient’s well-being dramatically but may also lead to restitution of morphological alterations [11]. Whether or not a related pathogenesis is responsible for the markedly increased association of pancreatic inflammation and/or insufficiency with inflammatory bowel diseases or celiac disease has remained speculative so far.

Immunologic alterations are not only potentially important aetiologic factors in chronic pancreatitis but also determine the progressive destructive inflammatory and fibrotic process that
ends in destruction of the organ. Some cytokines and growth factors at least partly exert their action by regulating activity of pancreatic stellate cells, which are of pivotal importance for development of pancreatic fibrosis [12]. Apart from activation via cytokines, direct activation of pancreatic stellate cells by ethanol via its metabolism to acetaldehyde and the generation of oxidant stress appears to be possible [13, 14]. These intriguing findings need to be expanded and further aspects of chronic pancreatic inflammation still need to be elucidated. Examples include the mechanisms that turn acute, reversible inflammation into a chronic destructive process and may eventually lead to pancreatic cancer. Such studies might help us to define the subgroup(s) of patients with chronic pancreatitis that are at high risk of developing malignancy.

Another unsolved question involves our difficulty to detect the disease in its initial stage. Early diagnosis of chronic pancreatitis is hampered by the lack of sensitive and widely available imaging and/or functional tests. Alterations of pancreatic ducts and tissue may be mild or even absent in patients with significant symptoms so that conventional diagnostic techniques such as abdominal ultrasound or CT are inconclusive. Thus, it has been a matter of debate whether ERCP or rather endoscopic ultrasound should be considered the golden standard for diagnosis of morphological alterations in chronic pancreatitis. Moreover, morphological changes may be absent in a subset of patients who present with loss of function only [15]. The role of (functional) MRCP as an alternative method has not been clarified convincingly so far.

With respect to pancreatic function testing the current situation is even more dissatisfying. Despite decades of research there is still no non-invasive pancreatic function test available that would allow reliable diagnosis of mild to moderate impairment of pancreatic exocrine function [16]. Indeed, our diagnostic armamentarium appears to be decreasing since tests like the Pankreolauryl® and PABA tests are no longer available. Potentially, 13C-breath tests may become important alternatives [17].

For the affected patient, optimisation of treatment modalities is of pivotal importance. Treatment should address typical symptoms of chronic pancreatitis such as flares of acute inflammation, chronic pain and pancreatic exocrine and endocrine insufficiency as well as optimal handling of further complications. However, many relevant problems that challenge the clinical pancreatologist in his daily practice remain a matter of controversial discussion. For instance, while many clinicians would agree that there is a certain role of interventional endoscopic or extracorporal shockwave lithotripsy (ESWL) therapy approaches, neither their benefits and potential indications nor their limitations and long-term hazards have been demonstrated in prospective randomised trials. Similarly unclear is the optimal therapeutic strategy in patients with chronic pain in the absence of local complications, and widely different conservative and surgical concepts are discussed controversially. Another developing area is the treatment of pancreatic exocrine insufficiency [18], which has become clearly more effective since the introduction of acid-resistant pancreatin microgranules, compared with traditional preparations consisting of pancreatin powder or acid resistant capsules. However, even with excessive doses, normalisation of steatorrhea is not possible in a relevant proportion of patients. Thus, the ideal pancreatic enzyme supplement still needs to be developed [19].

Limitations and difficulties like the ones depicted above continue to challenge our pathogenetic concepts in chronic pancreatitis, and we should keep in mind that many of our management strategies continue to be based on individual experience and beliefs rather than on controlled studies. On the other hand, it is equally important to acknowledge and take into account the substantial improvement of our understanding of the complex disease mechanisms witnessed by the past decade, and, perhaps, to utilise it as groundwork for further progress.

Correspondence:
Prof. Dr. Peter Layer
Ärztlicher Direktor
Direktor der Medizinischen Klinik
Israelitisches Krankenhaus
Lehrkrankenhaus der Universität Hamburg
Orchideenstieg 14
D-22297 Hamburg
E-Mail: layer@ik-h.de
References

The many reasons why you should choose SMW to publish your research

*What Swiss Medical Weekly has to offer:*

- SMW’s impact factor has been steadily rising, to the current 1.537
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

*Editorial Board*

Prof. Jean-Michel Dayer, Geneva
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich
(Editors in chief)
Prof. Werner Straub, Berne
Prof. Ludwig von Segesser, Lausanne

*International Advisory Committee*

Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialties, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors:
http://www.smw.ch/set_authors.html

*Impact factor Swiss Medical Weekly*

<table>
<thead>
<tr>
<th>Year</th>
<th>Impact Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>0.770</td>
</tr>
<tr>
<td>1996</td>
<td>0.864</td>
</tr>
<tr>
<td>1997</td>
<td>0.734</td>
</tr>
<tr>
<td>1998</td>
<td>1.162</td>
</tr>
<tr>
<td>2000</td>
<td>1.537</td>
</tr>
</tbody>
</table>

*EMH Swiss Medical Publishers Ltd.*
SMW Editorial Secretariat
Farnburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch

All manuscripts should be sent in electronic form, to: